CDNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CareDx Inc (CDNA) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock lacks clear positive momentum, has mixed analyst ratings, and faces financial challenges. While the company has shown revenue growth, its declining net income and EPS, along with uncertain policy impacts, make it prudent to hold off on buying at this time.
The technical indicators for CDNA are neutral to slightly bearish. The MACD is below zero and negatively contracting, the RSI is neutral at 42.323, and moving averages are converging. The stock is trading near its pivot level of 18.531, with key resistance at 19.551 and support at 17.511. Recent candlestick patterns suggest a 75% chance of a -1.64% decline in the next week and -5.84% in the next month.
The company delivered a strong Q4 2025 revenue growth of 25.19% YoY. Analysts from BTIG raised the price target to $26 and believe the stock is undervalued regardless of policy outcomes.
Policy uncertainty with CMS and restrictive draft LCDs pose risks to future growth. Craig-Hallum downgraded the stock to Hold, citing less compelling risk-reward and potential overestimation of future growth.
In Q4 2025, CareDx reported revenue growth of 25.19% YoY, reaching $108.39 million. However, net income fell to -$4.11 million (-105.27% YoY), and EPS dropped to -$0.08 (-107.14% YoY). Gross margin slightly declined to 67.24% (-0.31% YoY).
Analyst sentiment is mixed. BTIG maintains a Buy rating with a raised price target of $26, citing undervaluation. Craig-Hallum downgraded the stock to Hold with a $26 price target, expressing concerns about policy risks and future growth. Wells Fargo raised its price target to $18 but kept an Equal Weight rating.
